The Influence of St. John's Wort on the Pharmacokinetics and Protein Binding of Imatinib Mesylate

Patrick F. Smith, Pharm.D.; Julie M. Bullock, Pharm.D.; Brent M. Booker, Pharm.D.; Curtis E. Haas, Pharm.D.; Charles S. Berenson, M.D.; William J. Jusko, Ph.D.


Pharmacotherapy. 2004;24(11) 

In This Article


Administration of imatinib in patients taking St. John's wort significantly affected the pharmacokinetics of imatinib. Clinicians should be aware that St. John's wort may reduce imatinib exposure by 30-40% and should take appropriate actions to educate patients receiving imatinib. Awareness of the potential interactions between herbal products and anticancer agents will enable clinicians to take appropriate steps to ensure that such interactions do not unnecessarily compromise therapeutic outcomes.

Presented in part at the annual meeting of the American College of Clinical Pharmacy, Atlanta, Georgia, November 1-4, 2004.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.